• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Preconditioning mesenchymal stem cells with caspase inhibition and hyperoxia prior to hypoxia exposure increases cell proliferation.预先用半胱天冬酶抑制剂和高氧预处理间充质干细胞,然后再进行低氧暴露,可增加细胞增殖。
J Cell Biochem. 2013 Nov;114(11):2612-23. doi: 10.1002/jcb.24609.
2
Hypoxic Preconditioning Increases Survival and Pro-Angiogenic Capacity of Human Cord Blood Mesenchymal Stromal Cells In Vitro.低氧预处理可提高人脐带血间充质基质细胞的体外存活率和促血管生成能力。
PLoS One. 2015 Sep 18;10(9):e0138477. doi: 10.1371/journal.pone.0138477. eCollection 2015.
3
Protective effects of trimetazidine on bone marrow mesenchymal stem cells viability in an ex vivo model of hypoxia and in vivo model of locally myocardial ischemia.曲美他嗪对缺氧体外模型及局部心肌缺血体内模型中骨髓间充质干细胞活力的保护作用。
J Huazhong Univ Sci Technolog Med Sci. 2012 Feb;32(1):36-41. doi: 10.1007/s11596-012-0006-x. Epub 2012 Jan 27.
4
Hypoxic preconditioning improves the survival and neural effects of transplanted mesenchymal stem cells via CXCL12/CXCR4 signalling in a rat model of cerebral infarction.低氧预处理通过 CXCL12/CXCR4 信号通路改善脑梗死大鼠模型中移植间充质干细胞的存活和神经效应。
Cell Biochem Funct. 2019 Oct;37(7):504-515. doi: 10.1002/cbf.3423. Epub 2019 Jul 31.
5
Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection.预处理间充质干细胞与转化生长因子-α可改善间充质干细胞介导的心脏保护作用。
Shock. 2010 Jan;33(1):24-30. doi: 10.1097/SHK.0b013e3181b7d137.
6
Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells.低氧预处理诱导间充质干细胞中存活和促血管生成标志物的表达。
Am J Physiol Cell Physiol. 2010 Dec;299(6):C1562-70. doi: 10.1152/ajpcell.00221.2010. Epub 2010 Sep 22.
7
Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2.洛伐他汀通过激活PI3K/Akt和ERK1/2保护间充质干细胞免受缺氧和血清剥夺诱导的细胞凋亡。
J Cell Biochem. 2008 Jan 1;103(1):256-69. doi: 10.1002/jcb.21402.
8
A Large-Scale Investigation of Hypoxia-Preconditioned Allogeneic Mesenchymal Stem Cells for Myocardial Repair in Nonhuman Primates: Paracrine Activity Without Remuscularization.非人类灵长类动物中缺氧预处理的同种异体间充质干细胞用于心肌修复的大规模研究:无再肌化的旁分泌活性
Circ Res. 2016 Mar 18;118(6):970-83. doi: 10.1161/CIRCRESAHA.115.307516. Epub 2016 Jan 19.
9
Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction.长期抑制半胱天冬酶可改善细胞凋亡、减少心肌肌钙蛋白I的裂解、保护左心室功能并减轻心肌梗死大鼠的心肌重塑。
J Am Coll Cardiol. 2004 Jan 21;43(2):295-301. doi: 10.1016/j.jacc.2003.09.026.
10
let-7b suppresses apoptosis and autophagy of human mesenchymal stem cells transplanted into ischemia/reperfusion injured heart 7by targeting caspase-3.let-7b通过靶向半胱天冬酶-3抑制移植到缺血/再灌注损伤心脏中的人间充质干细胞的凋亡和自噬。
Stem Cell Res Ther. 2015 Aug 22;6(1):147. doi: 10.1186/s13287-015-0134-x.

引用本文的文献

1
Pretreatment with Notoginsenoside R1 enhances the efficacy of neonatal rat mesenchymal stem cell transplantation in model of myocardial infarction through regulating PI3K/Akt/FoxO1 signaling pathways.预处理 Notoginsenoside R1 通过调节 PI3K/Akt/FoxO1 信号通路增强新生大鼠间充质干细胞移植治疗心肌梗死模型的疗效。
Stem Cell Res Ther. 2024 Nov 13;15(1):419. doi: 10.1186/s13287-024-04039-x.
2
Combined effect of pantoprazole and mesenchymal stem cells on experimentally induced gastric ulcer: implication of oxidative stress, inflammation and apoptosis pathways.泮托拉唑联合间充质干细胞对实验性诱导胃溃疡的影响:氧化应激、炎症和细胞凋亡途径的作用。
Inflammopharmacology. 2024 Jun;32(3):1961-1982. doi: 10.1007/s10787-024-01469-0. Epub 2024 Apr 23.
3
Recent advances in pre-conditioned mesenchymal stem/stromal cell (MSCs) therapy in organ failure; a comprehensive review of preclinical studies.预处理间充质干细胞(MSCs)治疗器官衰竭的最新进展:临床前研究的综合综述。
Stem Cell Res Ther. 2023 Jun 7;14(1):155. doi: 10.1186/s13287-023-03374-9.
4
The promising role of hypoxia-resistant insulin-producing cells in ameliorating diabetes mellitus .耐缺氧胰岛素生成细胞在改善糖尿病方面的潜在作用。
Future Sci OA. 2022 Sep 14;8(7):FSO811. doi: 10.2144/fsoa-2022-0005. eCollection 2022 Aug.
5
Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges.间充质干细胞移植治疗缺血性疾病:机制与挑战。
Tissue Eng Regen Med. 2021 Aug;18(4):587-611. doi: 10.1007/s13770-021-00334-3. Epub 2021 Apr 21.
6
Substance P enhances the therapeutic effect of MSCs by modulating their angiogenic potential.P 物质通过调节间充质干细胞的血管生成潜能增强其治疗效果。
J Cell Mol Med. 2020 Nov;24(21):12560-12571. doi: 10.1111/jcmm.15804. Epub 2020 Sep 28.
7
State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery.细胞疗法治疗肺部疾病的最新研究进展,以及气溶胶输送的潜力。
Int J Mol Sci. 2020 Sep 3;21(17):6435. doi: 10.3390/ijms21176435.
8
Mesenchymal Stem Cell/Multipotent Stromal Cell Augmentation of Wound Healing: Lessons from the Physiology of Matrix and Hypoxia Support.间质干细胞/多能基质细胞促进伤口愈合:基质和缺氧支持生理学的启示。
Am J Pathol. 2020 Jul;190(7):1370-1381. doi: 10.1016/j.ajpath.2020.03.017. Epub 2020 Apr 12.
9
A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies.间充质干细胞疗法、临床前景及修饰策略的深度综述
Stem Cell Investig. 2019 Sep 25;6:34. doi: 10.21037/sci.2019.08.11. eCollection 2019.
10
Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction.功能改善的间充质干细胞用于更好地治疗心肌梗死
Stem Cells Int. 2018 Nov 25;2018:7045245. doi: 10.1155/2018/7045245. eCollection 2018.

本文引用的文献

1
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association.执行摘要:《2012年心脏病和中风统计数据更新:美国心脏协会报告》
Circulation. 2012 Jan 3;125(1):188-97. doi: 10.1161/CIR.0b013e3182456d46.
2
10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice.10 年的心脏冠状动脉内和心肌内骨髓干细胞治疗:从方法学起源到临床实践。
J Am Coll Cardiol. 2011 Sep 6;58(11):1095-104. doi: 10.1016/j.jacc.2011.06.016.
3
Genetic engineering of mesenchymal stem cells and its application in human disease therapy.间充质干细胞的基因工程及其在人类疾病治疗中的应用。
Hum Gene Ther. 2010 Nov;21(11):1513-26. doi: 10.1089/hum.2010.165. Epub 2010 Oct 22.
4
Pretreatment with hyperoxia reduces in vivo infarct size and cell death by apoptosis with an early and delayed phase of protection.预先给予高浓度氧可减少体内梗塞面积和细胞凋亡死亡,具有早期和晚期的保护作用。
Eur J Cardiothorac Surg. 2011 Feb;39(2):233-40. doi: 10.1016/j.ejcts.2010.05.036. Epub 2010 Jul 23.
5
Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease.心脏修复与再生:心脏病细胞治疗的魔方
Dis Model Mech. 2009 Jul-Aug;2(7-8):344-58. doi: 10.1242/dmm.000240.
6
Hyperbaric oxygenation enhances transplanted cell graft and functional recovery in the infarct heart.高压氧疗可增强梗死心脏中移植细胞移植物的存活及功能恢复。
J Mol Cell Cardiol. 2009 Aug;47(2):275-87. doi: 10.1016/j.yjmcc.2009.04.005. Epub 2009 Apr 17.
7
Stem cells and the phenomena of plasticity and diversity: a limiting property of carcinogenesis.干细胞与可塑性和多样性现象:致癌作用的一种限制特性。
Stem Cells Dev. 2008 Dec;17(6):1031-8. doi: 10.1089/scd.2007.0234.
8
Caspase inhibitor zVAD.fmk reduces infarct size after myocardial ischaemia and reperfusion in rats but not in mice.半胱天冬酶抑制剂zVAD.fmk可减小大鼠心肌缺血再灌注后的梗死面积,但对小鼠无效。
Resuscitation. 2008 Dec;79(3):468-74. doi: 10.1016/j.resuscitation.2008.07.008. Epub 2008 Sep 20.
9
Systems approaches to preventing transplanted cell death in cardiac repair.预防心脏修复中移植细胞死亡的系统方法。
J Mol Cell Cardiol. 2008 Oct;45(4):567-81. doi: 10.1016/j.yjmcc.2008.03.009. Epub 2008 Mar 19.
10
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation.缺血性心肌病成肌细胞自体移植(MAGIC)试验:成肌细胞移植的首个随机安慰剂对照研究。
Circulation. 2008 Mar 4;117(9):1189-200. doi: 10.1161/CIRCULATIONAHA.107.734103. Epub 2008 Feb 19.

预先用半胱天冬酶抑制剂和高氧预处理间充质干细胞,然后再进行低氧暴露,可增加细胞增殖。

Preconditioning mesenchymal stem cells with caspase inhibition and hyperoxia prior to hypoxia exposure increases cell proliferation.

机构信息

Department of Medicine, Division of Cardiovascular Medicine, The Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio.

出版信息

J Cell Biochem. 2013 Nov;114(11):2612-23. doi: 10.1002/jcb.24609.

DOI:10.1002/jcb.24609
PMID:23794477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4017598/
Abstract

Myocardial infarction is a leading cause of mortality and morbidity worldwide. Occlusion of a coronary artery produces ischemia and myocardial necrosis that leads to left ventricular (LV) remodeling, dysfunction, and heart failure. Stem cell therapy may decrease infarct size and improve LV function; the hypoxic environment, however, following a myocardial infarction may result in apoptosis, which in turn decreases survival of transplanted stem cells. Therefore, the effects of preconditioned mesenchymal stem cells (MSC) with hyperoxia (100% oxygen), Z-VAD-FMK pan-caspase inhibitor (CI), or both in a hypoxic environment in order to mimic conditions seen in cardiac tissue post-myocardial infarction were studied in vitro. MSCs preconditioned with hyperoxia or CI significantly decreased apoptosis as suggested by TUNEL assay and Annexin V analysis using fluorescence assisted cell sorting. These effects were more profound when both, hyperoxia and CI, were used. Additionally, gene and protein expression of caspases 1, 3, 6, 7, and 9 were down-regulated significantly in MSCs preconditioned with hyperoxia, CI, or both, while the survival markers Akt1, NF-κB, and Bcl-2 were significantly increased in preconditioned MSCs. These changes ultimately resulted in a significant increase in MSC proliferation in hypoxic environment as determined by BrdU assays compared to MSCs without preconditioning. These effects may prove to be of great clinical significance when transplanting stem cells into the hypoxic myocardium of post-myocardial infarction patients in order to attenuate LV remodeling and improve LV function.

摘要

心肌梗死是全球范围内导致死亡和发病的主要原因。冠状动脉阻塞会导致缺血和心肌坏死,从而导致左心室(LV)重构、功能障碍和心力衰竭。干细胞疗法可能会减小梗塞面积并改善 LV 功能;然而,心肌梗死后的缺氧环境可能导致细胞凋亡,进而降低移植干细胞的存活率。因此,本研究旨在体外模拟心肌梗死后心脏组织中所见的条件,研究预处理的间充质干细胞(MSC)在高氧(100%氧气)、Z-VAD-FMK 泛半胱天冬酶抑制剂(CI)或两者联合的缺氧环境中的作用。如 TUNEL 检测和荧光辅助细胞分选的 Annexin V 分析所示,高氧或 CI 预处理的 MSC 显著减少了细胞凋亡。当同时使用高氧和 CI 时,这种效果更为明显。此外,高氧、CI 或两者预处理的 MSC 中 caspase1、3、6、7 和 9 的基因和蛋白表达显著下调,而存活标志物 Akt1、NF-κB 和 Bcl-2 在预处理 MSC 中显著增加。与未经预处理的 MSC 相比,这些变化最终导致缺氧环境中 MSC 的增殖显著增加,通过 BrdU 测定法确定。当将干细胞移植到心肌梗死后的缺氧心肌中以减轻 LV 重构并改善 LV 功能时,这些作用可能具有重要的临床意义。